On the stock market since 2020, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 56% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 124% a year on average.
Sales run at $83.4M a year. A small number, but proof the product has real buyers.
It pays out $1.72 per share each year — regular cash for whoever holds the stock.
A loss of $5.0M against $83.4M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, JMPNZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: JMPNZ is a high-risk stock — not yet profitable, and its future rides on its product catching on.